Ginkgo Bioworks Holdings, Inc. (DNA) intrinsic value & 10-year financials
Ginkgo Bioworks Holdings, Inc. (DNA) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue grew 21.0% a year to $170.2M, with an average return on invested capital of -839.4%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $10.27
- Market cap
- $569.6M
- Revenue (FY2025)
- $170.2M
- Revenue growth (8-yr CAGR)
- 21.0%
- ROIC (10-yr avg)
- -839.4%
- Free cash flow (FY2025)
- -$178.7M
DNA 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $170.2M | -$312.8M | -$5.64 | -$178.7M | -185.3% | -46.5% |
| FY2024 | $227.0M | -$547.0M | -$10.54 | -$382.1M | -246.5% | -115.5% |
| FY2023 | $251.5M | -$892.9M | -$0.46 | -$336.3M | -343.8% | -143.0% |
| FY2022 | $477.7M | -$2.1B | -$1.25 | -$304.5M | -462.4% | -540.6% |
| FY2021 | $313.8M | -$1.8B | -$1.39 | -$310.3M | -582.6% | -4869.6% |
| FY2020 | $76.7M | -$126.6M | -$0.10 | -$193.7M | -178.8% | -140.7% |
| FY2019 | $54.2M | -$119.3M | -$0.10 | -$66.9M | -132.1% | -20.0% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Ginkgo Bioworks Holdings, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Ginkgo Bioworks Holdings, Inc. has historically struggled to out-earn its cost of capital, averaging just -83.3% ROIC.
Ginkgo Bioworks Holdings, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, Ginkgo Bioworks Holdings, Inc. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-187.34 per share.